-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310

Benzinga·10/20/2026 13:55:47
Listen to the news
Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $250 to $310.